NCT05858736 - Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 15, 2026

Conditions

MelanomaNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerCervical CancerRenal Cell CarcinomaBladder CancerEsophageal CancerGastric CancerGastroesophageal-junction CancerColorectal CancerAnal CancerHepatocellular CarcinomaBile Duct Cancer

Interventions

DRUG

AI-061

A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.

Trial Locations (5)

2010

St. Vincent's Private Hospital, Darlinghurst

4006

Mater Misericordiae Ltd., Brisbane

4120

Tasman Oncology Research, Southport

5000

Cancer Research SA, Adelaide

5042

Southern Oncology Clinical Research Unit, Bedford Park